Search results for "Factor receptor"

showing 10 items of 350 documents

The role of extracellular calcium in bone metastasis

2016

AbstractThis review summarizes the role of extracellular calcium, as found present in the bone tissue, in the process of bone metastasis.

0301 basic medicinelcsh:Diseases of the musculoskeletal systemIGF insulin-like growth factorPGE-2 prostaglandin E-2Bone tissueFibroblast growth factorM-CSF macrophage colony-stimulating factorPDGF platelet-derived growth factorBone remodelingSK3 small conductance calcium-activated potassium channel 30302 clinical medicineERK extracellular signal-regulated kinaseTGFβ transforming growth factor betaBMP's bone morphogenetic proteinsbiologyAKT AKT8 virus oncogene cellular homologBone metastasislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanitiescAMP cyclic adenosine monophosphatemedicine.anatomical_structureOncologyRANKL030220 oncology & carcinogenesisIon channelsCaSR calcium-sensing receptorPTHrP parathyroid hormone-related proteinPlatelet-derived growth factor receptorResearch PaperTRP transient receptor potentialmedicine.medical_specialtychemistry.chemical_elementCalciumRANKL receptor activator of NF-κB ligandlcsh:RC254-28203 medical and health sciencesPLC phospholipase CInternal medicinemedicineExtracellularCaSRET-1 endothelin-1PTEN phosphatase and tensin homolog deleted on chromosome 10business.industryBone metastasismedicine.diseaseFGF fibroblast growth factor030104 developmental biologyEndocrinologyPSA prostate specific antigenchemistryCOPD chronic obstructive pulmonary diseasebiology.proteinCancer researchJNK jun N-terminal kinasePKA protein kinase ARANK receptor activator of NF-κBCalciumlcsh:RC925-935businessMAPK mitogen-activated protein kinaseJournal of Bone Oncology
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

2017

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.

0301 basic medicinemedicine.medical_specialtyPathologyReceptor Platelet-Derived Growth Factor alphamedicine.medical_treatmentPDGFR-αAntineoplastic AgentsTargeted therapy03 medical and health sciences0302 clinical medicineGrowth factor receptorDoxorubicin; Olaratumab; PDGFR-α; Soft tissue sarcomas; Hematology; Oncology; Geriatrics and GerontologyInternal medicinemedicineHumansDoxorubicinOlaratumabSoft tissue sarcomaHematologybiologybusiness.industryAntibodies MonoclonalCancerSoft tissueSarcomaHematologySoft tissue sarcomasmedicine.disease030104 developmental biologyOncologyDoxorubicin030220 oncology & carcinogenesisbiology.proteinGeriatrics and GerontologybusinessPlatelet-derived growth factor receptormedicine.drugOlaratumab
researchProduct

Influence of platelet-derived growth factor on osseous remodeling properties of a variable-thread tapered dental implant in vivo

2016

Objectives To evaluate the effect of platelet-derived growth factor (rhPDGF-BB) on the promotion of osteogenesis around variable-thread tapered implants in an animal model. Material and methods Twenty-four variable-thread tapered implants were inserted in the tibia of 12 rabbits. Twelve sites received additional rhPDGF-BB released from a presoaked xenogenic bone block that was fixed supracrestally. Primary outcomes were bone-to-implant contact (BIC; in % ± SD) and percentage of medullary bone fill around the implants (PMF; in % ± SD) after 3 weeks (PDGF n = 6, no PDGF n = 6) and 6 weeks (PDGF n = 6, no PDGF n = 6). Results Considerable crestal and medullary bone remodeling could be found ar…

0301 basic medicinemedicine.medical_specialtyPlatelet-derived growth factorMedullary cavitymedicine.medical_treatmentDentistryOsseointegrationBone remodeling03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImplants ExperimentalInternal medicinemedicineAnimalsProspective StudiesTibiaDental implantDental ImplantsPlatelet-Derived Growth FactorTibiabiologybusiness.industryGrowth factor030206 dentistry030104 developmental biologyEndocrinologychemistryModels Animalbiology.proteinBone RemodelingRabbitsOral SurgerybusinessPlatelet-derived growth factor receptorClinical Oral Implants Research
researchProduct

Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren’s disease

2016

The mechanism by which the fibroblast is able to trigger palmar fibromatosis is still not yet fully understood. It would appear certain that the “abnormal” fibroblasts continuously synthesise profibrotic cytokines which are able to determine the activation to myofibroblasts, to stimulate them to the further proliferation and synthesis of other cytokines, to modify the cells’ differentiation and ultrastructural characteristics, as well as the production of matrix and other proteins. Several fibroblast growth factors have been suggested to be responsible of an abnormal cell activation with an aberrantly elevated collagen synthesis and extracellular deposition in Dupuytren’s disease, as TGF-Be…

0301 basic medicinemedicine.medical_specialtySettore MED/19 - Chirurgia PlasticaReviewMatrix metalloproteinaseFibroblast growth factorBiochemistryPathogenesis03 medical and health sciences0302 clinical medicineInternal medicinemedicineExtracellularFibroblastMolecular BiologyCytokines Fibroblast Dupuytren’s disease030222 orthopedicsbiologyCell Biology030104 developmental biologyEndocrinologymedicine.anatomical_structurebiology.proteinCancer researchMyofibroblastPlatelet-derived growth factor receptorPalmar Fibromatosis
researchProduct

2021

Receptor tyrosine kinase inhibitors have become a central part of modern targeted cancer therapy. However, their curative potential is distinctly limited by both rapid resistance development and severe adverse effects. Consequently, tumor-specific drug activation based on prodrug designs, exploiting tumor-specific properties such as hypoxic oxygen conditions, is a feasible strategy to widen the therapeutic window. After proof-of-principal molecular docking studies, we have synthesized two cobalt(iii) complexes using a derivative of the clinically approved Abelson (ABL) kinase and fibroblast growth factor receptor (FGFR) inhibitor ponatinib. Acetylacetone (acac) or methylacetylacetone (Meaca…

0303 health sciencesABLmedicine.drug_classChemistryKinasePonatinibProdrugTyrosine-kinase inhibitorIn vitroInorganic Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoFibroblast growth factor receptor030220 oncology & carcinogenesisCancer researchmedicine030304 developmental biologyInorganic Chemistry Frontiers
researchProduct

Echovirus 1 infection depends on biogenesis of novel multivesicular bodies

2011

Summary Non-enveloped picornavirus echovirus 1 (EV1) clusters its receptor α2β1 integrin and causes their internalization and accumulation in α2β1 integrin enriched multivesicular bodies (α2-MVBs). Our results here show that these α2-MVBs are distinct from acidic late endosomes/lysosomes by several criteria: (i) live intra-endosomal pH measurements show that α2-MVBs are not acidic, (ii) they are not positive for the late endosomal marker LBPA or Dil-LDL internalized to lysosomes, and (iii) simultaneous stimulation of epidermal growth factor receptor (EGFR) and α2β1 integrin clustering leads to their accumulation in separate endosomes. EGFR showed downregulation between 15 min and 2 h, where…

0303 health sciencesbiologyEndosomemedia_common.quotation_subject030302 biochemistry & molecular biologyImmunologyIntegrinmacromolecular substancesMicrobiology3. Good healthCell biology03 medical and health sciencesDownregulation and upregulationVirologybiology.proteinTSG101Epidermal growth factor receptorReceptorInternalizationBiogenesis030304 developmental biologymedia_commonCellular Microbiology
researchProduct

Surface plasmon resonance signal enhancement based on erlotinib loaded magnetic nanoparticles for evaluation of its interaction with human lung cance…

2021

Abstract Surface plasmon resonance (SPR) sensor provides a very useful tool based on its label-free, real-time monitoring and low price properties. However, measurement of small molecules and extremely diluted analytes is difficult and therefore, signal enhancement is required. In the present study, signal enhancement of erlotinib conjugated magnetic nanoparticles (erlotinib-MNPs) compared to erlotinib was evaluated via their interaction with overexpressed epidermal growth factor receptor on human lung cancer cells (A549 cell line) surface using SPR sensor at three temperature levels. The attained results showed an average signal amplification of about 2.5-fold for MNP-erlotinib interaction…

A549 cellbiologyChemistry010401 analytical chemistry02 engineering and technologyConjugated system021001 nanoscience & nanotechnology01 natural sciencesSmall moleculeAtomic and Molecular Physics and Opticsrespiratory tract diseases0104 chemical sciencesElectronic Optical and Magnetic MaterialsCancer cellmedicinebiology.proteinBiophysicsMagnetic nanoparticlesErlotinibEpidermal growth factor receptorElectrical and Electronic EngineeringSurface plasmon resonance0210 nano-technologymedicine.drugOptics & Laser Technology
researchProduct

Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction

2014

ObjectiveTo determine the release kinetics of different biomarkers with potential as novel early ischaemic biomarkers in patients with acute coronary syndrome (ACS); it is difficult to establish the detailed release kinetics in patients with acute myocardial infarction (AMI).MethodsWe analysed the release kinetics of soluble fms-like tyrosine kinase (sFlt-1), ischaemia modified albumin (IMA), and heart-type fatty acid binding protein (hFABP) in patients with hypertrophic obstructive cardiomyopathy who were undergoing transcoronary ablation of septal hypertrophy (TASH), a procedure mimicking AMI. Consecutive patients (n=21) undergoing TASH were included. Blood samples were collected before T…

Ablation TechniquesMalemedicine.medical_specialtyAcute coronary syndromeMyocardial InfarctionCardiomyopathySerum albuminSerum Albumin HumanFatty Acid-Binding ProteinsFatty acid-binding proteinPredictive Value of TestsInternal medicineHumansMedicineMyocardial infarctionSerum AlbuminAgedImmunoassayVascular Endothelial Growth Factor Receptor-1biologybusiness.industryCardiomyopathy HypertrophicMiddle Agedmedicine.diseaseUp-RegulationKineticsEarly DiagnosisPredictive value of testsbiology.proteinCardiologyFemaleFatty Acid Binding Protein 3Myocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessFatty Acid Binding Protein 3BiomarkersHeart
researchProduct

A double-negative (IgD−CD27−) B cell population is increased in the peripheral blood of elderly people

2009

The T cell branch of the immune system has been extensively studied in the elderly and it is known that the elderly have impaired immune function, mainly due to the chronic antigenic load that ultimately causes shrinkage of the T cell repertoire and filling of the immunologic space with memory T cells. In the present paper, we describe the IgD(-)CD27(-) double-negative B cell population which (as we have recently described) is higher in the elderly. Most of these cells were IgG(+). Evaluation of the telomere length and expression of the ABCB1 transporter and anti-apoptotic molecule, Bcl2, shows that they have the markers of memory B cells. We also show that these cells do not act as antigen…

AdultAgingATP Binding Cassette Transporter Subfamily BT cellAntigens CD19B-Lymphocyte Subsetschemical and pharmacologic phenomenaYoung AdultB lymphocyte Immunosenescence IgD CD27 Elderly Immunologic memorymedicineHumansCytotoxic T cellATP Binding Cassette Transporter Subfamily B Member 1IL-2 receptorCD40 AntigensCD154Antigen-presenting cellCells CulturedAgedAged 80 and overSettore MED/04 - Patologia Generalebusiness.industryAge FactorsHLA-DR AntigensImmunoglobulin DMiddle AgedTelomereFlow CytometryAcquired immune systemTumor Necrosis Factor Receptor Superfamily Member 7B-1 cellKi-67 Antigenmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ImmunologyB7-1 AntigenbusinessImmunologic MemoryCD80Developmental BiologyMechanisms of Ageing and Development
researchProduct